株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

網膜芽細胞腫:パイプライン製品の分析

Retinoblastoma - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 192809
出版日 ページ情報 英文 60 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
網膜芽細胞腫:パイプライン製品の分析 Retinoblastoma - Pipeline Review, H2 2016
出版日: 2016年10月30日 ページ情報: 英文 60 Pages
概要

網膜芽細胞腫は網膜から発生する眼癌です。網膜芽細胞腫の発症は幼児期がほとんどですが、稀に成人でも発症することがあります。

当レポートでは、世界各国での網膜芽細胞腫治療法のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

網膜芽細胞腫の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

網膜芽細胞腫:企業で開発中の治療薬

網膜芽細胞腫:大学/機関で研究中の治療薬

網膜芽細胞腫:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

網膜芽細胞腫:企業で開発中の製品

網膜芽細胞腫:大学/機関で研究中の製品

網膜芽細胞腫の治療薬開発に従事している企業

  • BioLineRx, Ltd.
  • Cellceutix Corporation
  • Icon Bioscience, Inc.
  • Recombio S.L
  • RXi Pharmaceuticals Corporation

網膜芽細胞腫:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

網膜芽細胞腫:最近のパイプライン動向

網膜芽細胞腫:休止中のプロジェクト

網膜芽細胞腫:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8624IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinoblastoma - Pipeline Review, H2 2016, provides an overview of the Retinoblastoma (Oncology) pipeline landscape.

Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling. The predisposing factors include age and heredity. Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinoblastoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Retinoblastoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinoblastoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Retinoblastoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.Retinoblastoma.

Retinoblastoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinoblastoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Retinoblastoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinoblastoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinoblastoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinoblastoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinoblastoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinoblastoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinoblastoma Overview
  • Therapeutics Development
    • Pipeline Products for Retinoblastoma - Overview
    • Pipeline Products for Retinoblastoma - Comparative Analysis
  • Retinoblastoma - Therapeutics under Development by Companies
  • Retinoblastoma - Therapeutics under Investigation by Universities/Institutes
  • Retinoblastoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Retinoblastoma - Products under Development by Companies
  • Retinoblastoma - Products under Investigation by Universities/Institutes
  • Retinoblastoma - Companies Involved in Therapeutics Development
    • BioLineRx, Ltd.
    • Cellceutix Corporation
    • Icon Bioscience, Inc.
    • Recombio S.L
  • Retinoblastoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • BL-8040 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FL-118X - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Kevetrin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melphalan - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nutlin-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • racotumomab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target TFDP3 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Retinoblastoma - Dormant Projects
  • Retinoblastoma - Product Development Milestones
    • Featured News & Press Releases
      • Dec 01, 2015: Cellceutix Receives Rare Pediatric Disease Designation From FDA for Kevetrin for the Treatment of Retinoblastoma
      • Nov 23, 2015: Cellceutix Receives FDA Orphan Drug Designation for Kevetrin for the Treatment of Retinoblastoma
      • Aug 23, 2015: Cellceutix Requesting Meeting With FDA on Kevetrin for Pediatric Retinoblastoma
      • Mar 08, 2013: Cellceutix Announces Positive Preclinical Trial Data Of Kevetrin In Retinoblastoma
      • Jan 03, 2013: Icon's Melphalan Intraocular Injection Receives US Orphan Drug Designation For Treatment Of Retinoblastoma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Retinoblastoma, H2 2016
  • Number of Products under Development for Retinoblastoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Retinoblastoma - Pipeline by BioLineRx, Ltd., H2 2016
  • Retinoblastoma - Pipeline by Cellceutix Corporation, H2 2016
  • Retinoblastoma - Pipeline by Icon Bioscience, Inc., H2 2016
  • Retinoblastoma - Pipeline by Recombio S.L, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Retinoblastoma - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Retinoblastoma, H2 2016
  • Number of Products under Development for Retinoblastoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top